Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px
Document › Details

Jecure Therapeutics Inc.. (11/27/18). "Press Release: Genentech Acquires Jecure Therapeutics". San Diego, CA.

Organisations Organisation Jecure Therapeutics Inc.
  Group Roche (Group)
  Organisation 2 Genentech Inc.
  Group Roche (Group)
Product Product  venture capital
Index term Index term Jecure Therapeutics–Roche: investment, 201811 acquisition of Jecure by Genentech from Versant Ventures
Persons Person Stafford, Jeffrey A. (Jecure Therapeutics 201811 CEO)
  Person 2 Sabry, James H. (Roche 201808– Global Head Partnering joined Genentech 2010 before Arete Therapeutics + Cytokinetics)
     


Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, today announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group. With this acquisition, Genentech will obtain full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors.

“Genentech has an extensive history of translating pioneering science into transformative medicines,” said Jeffrey A. Stafford, Ph.D., president and CEO of Jecure. “The acquisition of Jecure provides a unique opportunity to bring novel NLRP3 inhibitors to patients.”

“We’ve had a long-standing interest in targeting inflammatory pathways that may play a role in a number of serious diseases,” said James Sabry, M.D., Ph.D., global head of Pharma Partnering, Roche. “We’re excited to combine Jecure’s portfolio with our discovery and development capabilities, as well as our expertise in NLRP3 biology, to potentially help people with inflammatory diseases.”

Jecure began operations in 2015 with a seed financing from founding investor Versant Ventures. The company raised $20 million in a Series A round from Versant in 2017 to continue to develop and advance its portfolio of NLRP3 inhibitors.


About NLRP3 and its Role in Inflammatory Disease

Nucleotide-binding oligomerization (NOD)-like Receptor Family Pyrin Domain Containing Protein 3 (NLRP3) is an immunomodulatory protein involved in the activation of certain inflammasomes, protein complexes responsible for the activation of cellular inflammatory responses. Studies have linked cellular stress signals to the activation of NLRP3 inflammasomes in a wide range of inflammatory and autoimmune disorders, such as non-alcoholic steatohepatitis (NASH), liver fibrosis, gout, inflammatory bowel disease (IBD) and cardiovascular diseases.


About Jecure Therapeutics

Jecure Therapeutics is focused on the discovery of novel therapeutics for the treatment of NASH and liver fibrosis. Jecure’s scientific founder is Dr. Ariel Feldstein, Division Chief of Gastroenterology at UCSD School of Medicine and a leading physician scientist in hepatology. With operations in the biotech hub of San Diego, California, Jecure combines emerging NASH biology from Dr. Feldstein’s lab, a proprietary liver disease platform and an elite discovery team of veteran pharma/biotech scientists. Jecure’s lead program has identified small molecule inhibitors of the NLRP3 inflammasome, a novel target and pro-inflammatory driver of NASH. Jecure is backed by top-tier life science investor Versant Ventures. For more information, please visit www.jecuretx.com.


Contacts

For Genentech or Jecure:
Susan Willson
650-467-6800
willsons@gene.com

For Versant:
Steve Edelson
415-801-8088
sedelson@versantventures.com

   
Record changed: 2018-11-29

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for Roche (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top